State Street Corp Grows Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

State Street Corp grew its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 8.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,728,888 shares of the company's stock after acquiring an additional 137,145 shares during the quarter. State Street Corp owned about 3.26% of Stoke Therapeutics worth $21,248,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its holdings in Stoke Therapeutics by 1,589.7% in the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock worth $936,000 after purchasing an additional 71,647 shares during the last quarter. RTW Investments LP grew its holdings in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after acquiring an additional 427,447 shares during the period. Los Angeles Capital Management LLC increased its position in Stoke Therapeutics by 54.3% during the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company's stock valued at $1,266,000 after acquiring an additional 36,240 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock valued at $18,741,000 after acquiring an additional 1,123,500 shares during the period. Finally, Millennium Management LLC lifted its holdings in Stoke Therapeutics by 528.6% in the second quarter. Millennium Management LLC now owns 289,067 shares of the company's stock valued at $3,905,000 after acquiring an additional 243,083 shares during the period.

Insider Activity at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 13,666 shares of Stoke Therapeutics stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the sale, the general counsel now directly owns 21,476 shares of the company's stock, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the transaction, the chief executive officer now directly owns 68,671 shares of the company's stock, valued at approximately $877,615.38. The trade was a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,849 shares of company stock valued at $809,421. Corporate insiders own 11.30% of the company's stock.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock traded down $0.29 during trading hours on Tuesday, hitting $11.32. The company's stock had a trading volume of 517,326 shares, compared to its average volume of 751,089. Stoke Therapeutics, Inc. has a 12-month low of $4.09 and a 12-month high of $17.58. The business has a 50 day moving average price of $12.46 and a two-hundred day moving average price of $13.49. The company has a market cap of $599.59 million, a PE ratio of -5.39 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Analysts Set New Price Targets

STOK has been the subject of a number of recent research reports. Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Friday, October 11th. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an "outperform" rating and a $18.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Finally, Chardan Capital initiated coverage on Stoke Therapeutics in a research note on Friday. They issued a "buy" rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of "Buy" and an average price target of $21.29.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.